WO 2013/151667 Al 10 October 2013 (10.10.2013) P O P C T

Total Page:16

File Type:pdf, Size:1020Kb

WO 2013/151667 Al 10 October 2013 (10.10.2013) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/151667 Al 10 October 2013 (10.10.2013) P O P C T (51) International Patent Classification: 61/681,720 10 August 2012 (10.08 2012) US C07H 21/00 (2006.01) 61/681,742 10 August 2012 (10.08 2012) US 61/681,649 10 August 2012 (10.08 2012) us (21) International Application Number: 61/681,645 10 August 2012 (10.08 2012) us PCT/US20 13/030063 61/681,661 10 August 2012 (10.08 2012) us (22) International Filing Date: 61/681,650 10 August 2012 (10.08 2012) us March 2013 (09.03.2013) 61/681,712 10 August 2012 (10.08 2012) us 61/696,381 4 September 2012 (04.09 2012) us (25) Filing Language: English 61/709,303 3 October 2012 (03 10 2012) us (26) Publication Language: English 61/712,490 11 October 2012 ( 11 10 2012) us 61/737,168 14 December 2012 (14 12 2012) us (30) Priority Data: 61/737,203 14 December 2012 (14 12 2012) us 61/618,862 2 April 2012 02.04 2012 US 61/737,155 14 December 2012 (14 12 2012) us 61/618,866 2 April 2012 02.04 2012 us 61/737,213 14 December 2012 (14 12 2012) us 61/618,868 2 April 2012 02.04 2012 us 61/737,134 14 December 2012 (14 12 2012) us 61/618,870 2 April 2012 02.04 2012 us 61/737,174 14 December 2012 (14 12 2012) us 61/618,873 2 April 2012 02.04 2012 us 61/737,139 14 December 2012 (14 12 2012) us 61/618,878 2 April 2012 02.04 2012 us 61/737,152 14 December 2012 (14 12 2012) us 61/618,885 2 April 2012 02.04 2012 us 61/737,184 14 December 2012 (14 12 2012) us 61/618,896 2 April 2012 02.04 2012 us 61/737,160 14 December 2012 (14 12 2012) us 61/618,91 1 2 April 2012 02.04 2012 us 61/737,135 14 December 2012 (14 12 2012) us 61/618,922 2 April 2012 02.04 2012 us 61/737,191 14 December 2012 (14 12 2012) us 61/618,935 2 April 2012 02.04 2012 us 61/737,130 14 December 2012 (14 12 2012) us 61/618,945 2 April 2012 02.04 2012 us 61/737,147 14 December 2012 (14 12 2012) us 61/618,953 2 April 2012 02.04 2012 us 61/618,961 2 April 2012 02.04 2012 us (71) Applicant: MODERNA THERAPEUTICS [US/US]; 61/618,957 2 April 2012 02.04 2012 us 161 First Street, First Floor, Cambrid ge, Massachusetts 61/648,286 17 May 2012 17.05 2012 us 02142 (US). 61/648,244 17 May 2012 17.05 2012 us (72) Inventors: BANCEL, Stephane; 68 Pinckney Road, Bo 61/668,157 5 July 2012 05.07 2012 us ston, Massachusetts 021 14 (US). CHAKRABORTY, 61/681,667 10 August 2012 10.08 2012 us Tirtha; 153 Woburn Street, Medford, Massachusetts 61/681,648 10 August 2012 10.08 2012 us 02155 (US). DE FOUGEROLLES, Antonin; 66 Summit 61/681,675 10 August 2012 10.08 2012 us Avenue, Brookline, Massachusetts 02446 (US). EL- 61/681,654 10 August 2012 10.08 2012 us BASHIR, Sayda M.; 149 Grove Street, Cambridge, Mas 61/681,687 10 August 2012 10.08 2012 us sachusetts 02138 (US). JOHN, Matthias; 338 Harvard St. 10 August 2012 10.08 2012 61/681,647 us #5, Cambridge, Massachusetts 02138 (US). ROY, Atanu; 61/681,696 10 August 2012 10.08 2012 us 115 Hill Street #9, Stoneham, Massachusetts 02180 (US). 61/681,658 10 August 2012 10.08 2012 us WHORISKEY, Susan; 47 Louise Road, Belmont, Mas 61/681,704 10 August 2012 10.08 2012 us sachusetts 02478 (US). WOOD, Kristy M.; 501 Huron [Continued on nextpage] (54) Title: MODIFIED POLYNUCLEOTIDES FIGURE 1 100 1 S 107 110 , a 104 03 106 (57) Abstract: Described herein are compositions, methods, processes, kits and devices for the design, preparation, manufacture and/or formulation of modified mRNA (mmRNA) molecules. The details of various embodiments of the invention are set forth in o the description below. Other features, objects, and advantages of the invention will be apparent from the description and the draw ings, and from the claims. The foregoing and other objects, features and advantages will be apparent from the following description of particular embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to o the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illus - trating the principles of various embodiments of the invention. w o 2013/151667 Ai llll II II 11III III I II II III II II III II I II Ave, Unit 2 , Cambridge, Massachusetts 02138 (US). RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, HAT ALA, Paul; 26 Monument Street #1, Charlestown, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, Massachusetts 02124 (US). SCHRUM, Jason P.; 4601 ZA, ZM, ZW. Flat Rock Road, Apt. 4 17, Philadelphia, Pennsylvania (84) Designated States (unless otherwise indicated, for every 19127 (US). EJEBE, Kenechi; 208 Pearl Street, Apt. 1, kind of regional protection available): ARIPO (BW, GH, Cambridge, Massachusetts 02139 (US). ELLSWORTH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, Jeff Lynn; 23 Meriam Street, Lexington, Massachusetts UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 02420 (US). GUILD, Justin; 495 Edgell Rd, Framing- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, ham, Massachusetts 01701 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (74) Agent: WARD, Donna T.; Dt Ward, P.C., 142A Main LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Street, Groton, Massachusetts 01450 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, Published: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, — with international search report (Art. 21(3)) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, — before the expiration of the time limit for amending the GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, claims and to be republished in the event of receipt of KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, amendments (Rule 48.2(h)) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, — with sequence listing part of description (Rule 5.2(a)) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, MODIFIED POLYNUCLEOTIDES REFERENCE TO SEQUENCE LISTING [0001] The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing file entitled M301_PCTSQLST.txt, was created on March 9, 2013 and is 104,018 bytes in size. The information in electronic format of the Sequence Listing is incorporated herein by reference in its entirety. CROSS REFERENCE TO RELATED APPLICATIONS [0002] This application claims priority to U.S. Provisional Patent Application No 61/681,742, filed, August 10, 2012, entitled Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides, U.S. Provisional Patent Application No 61/737,224, filed December 14, 2012, entitled Terminally Optimized Modified RNAs, International Application No PCT/US2012/069610, filed December 14, 2012, entitled Modified Nucleoside, Nucleotide, and Nucleic Acid Compositions, U.S. Provisional Patent Application No 61/618,862, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Biologies, U.S. Provisional Patent Application No 61/681,645, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Biologies, U.S. Provisional Patent Application No 61/737,130, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Biologies, U.S. Provisional Patent Application No 61/618,866, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Antibodies, U.S. Provisional Patent Application No 61/681,647, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Antibodies, U.S. Provisional Patent Application No 61/737,134, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Antibodies, U.S. Provisional Patent Application No 61/618,868, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Vaccines, U.S. Provisional Patent Application No 61/681,648, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Vaccines, U.S. Provisional Patent Application No 61/737,135, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Vaccines, U.S. Provisional Patent Application No 61/618,870, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides, U.S. Provisional Patent Application No 61/681,649, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides, U.S. Provisional Patent Application No 61/737,139, filed December 14, 2012, Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides, U.S. Provisional Patent Application No 61/618,873, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Secreted Proteins, U.S.
Recommended publications
  • The Bill & Melinda Gates Foundation Tax Return Was E-Filed with The
    The Bill & Melinda Gates Foundation tax return was e-filed with the Internal Revenue Service. The tax return and accompanying attachments posted on our website are presented as a view of the electronically filed data. Please note for ease of navigating the tax return we have bookmarked the various sections of the return. efile GRAPHIC print - DO NOT PROCESS ORIGINAL DATA - EIN: 562618866 Return of Private Foundation OMB No. 1545-0052 Form 990-PF or Section 4947(a)(1) Nonexempt Charitable Trust Treated as a Private Foundation 2007 Department of the Treasury Note: The foundation may be able to use a copy of this return to satisfy state reporting requirements. Internal Revenue Service For calendar year 2007 , or tax year beginning 01-01-2007 and ending 12-31-2007 G Check all that apply: Initial return Final return Amended return Address change Name change Name of foundation A Employer identification number Use the IRS BILL & MELINDA GATES FOUNDATION label. 56-2618866 Otherwise, B Telephone number (see page 10 of the instructions) print Number and street (or P.O. box number if mail is not delivered to street address) Room/ suite or type. 1551 EASTLAKE AVENUE EAST (206) 709-3100 See Specific Instructions. City or town, state, and ZIP code C If exemption application is pending, check here SEATTLE, WA 98102 D 1. Foreign organizations, check here . H Check type of organization: Section 501(c)(3) exempt private foundation 2. Foreign organizations meeting the 85% test, check here and attach computation Section 4947(a)(1) nonexempt charitable trust Other taxable private foundation E If private foundation status was terminated I Fair market value of all assets at end J Accounting method: Cash Accrual under section 507(b)(1)(A), check here of year (from Part II, col.
    [Show full text]
  • Developing Vaccines for Neglected Diseases
    Developing Vaccines for Neglected Diseases Vaccine Technologies II Albufeira, Portugal June 5th, 2008 Douglas Holtzman, Ph.D., M.P.H. Senior Program Officer, Global Health Program Bill & Melinda Gates Foundation 1 Three Programs, One Goal: Equity US Program » High school education » Public library internet access Global Development » Financial services for the poor (e.g. microfinance) » Agricultural productivity and markets Global Health 2 Perspective on Global Health The vision: To ensure that a child born in the developing world has the same chance for good health as a child born in the developed world The goal: Build on advances in science and technology to save lives, improve health, and reduce disease in the developing world 3 Prioritization Burden of disease Inequity of burden Lack of attention Possibility for impact 4 Disease Areas HIV (vaccines, microbicides, treatment, prevention, education) TB (drugs, vaccines, diagnostics) Malaria (drugs, vaccines, vector control, diagnostics, scale-up) Pneumonia Diarrhea Nutrition Maternal Health Discover, develop and deliver Kinetoplastids innovative solutions Helminths HPV Dengue/Japanese Encephalitis Polio 5 Partnerships Global Alliance for Vaccines and Immunization (GAVI) Global Fund for AIDS, TB and Malaria HIV Vaccine Enterprise Medicines for Malaria Venture (MMV) Malaria Vaccine Initiative (MVI) MACEPA PATH Vaccine Solutions (PVS) Aeras (TB Vaccines) Global Alliance for TB Drug Development (GATB) ACHAP Grand Challenges in Global Health IVI/PDVI Etc….
    [Show full text]
  • Infectious Diseases
    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
    [Show full text]
  • CLINICAL TRIALS Safety and Immunogenicity of a Nicotine Conjugate Vaccine in Current Smokers
    CLINICAL TRIALS Safety and immunogenicity of a nicotine conjugate vaccine in current smokers Immunotherapy is a novel potential treatment for nicotine addiction. The aim of this study was to assess the safety and immunogenicity of a nicotine conjugate vaccine, NicVAX, and its effects on smoking behavior. were recruited for a noncessation treatment study and assigned to 1 of 3 doses of the (68 ؍ Smokers (N nicotine vaccine (50, 100, or 200 ␮g) or placebo. They were injected on days 0, 28, 56, and 182 and monitored for a period of 38 weeks. Results showed that the nicotine vaccine was safe and well tolerated. Vaccine immunogenicity was dose-related (P < .001), with the highest dose eliciting antibody concentrations within the anticipated range of efficacy. There was no evidence of compensatory smoking or precipitation of nicotine withdrawal with the nicotine vaccine. The 30-day abstinence rate was significantly different across with the highest rate of abstinence occurring with 200 ␮g. The nicotine vaccine appears ,(02. ؍ the 4 doses (P to be a promising medication for tobacco dependence. (Clin Pharmacol Ther 2005;78:456-67.) Dorothy K. Hatsukami, PhD, Stephen Rennard, MD, Douglas Jorenby, PhD, Michael Fiore, MD, MPH, Joseph Koopmeiners, Arjen de Vos, MD, PhD, Gary Horwith, MD, and Paul R. Pentel, MD Minneapolis, Minn, Omaha, Neb, Madison, Wis, and Rockville, Md Surveys show that, although about 41% of smokers apy, is about 25% on average.2 Moreover, these per- make a quit attempt each year, less than 5% of smokers centages most likely exaggerate the efficacy of are successful at remaining abstinent for 3 months to a intervention because these trials are typically composed year.1 Smokers seeking available behavioral and phar- of subjects who are highly motivated to quit and who macologic therapies can enhance successful quit rates are free of complicating diagnoses such as depression 2 by 2- to 3-fold over control conditions.
    [Show full text]
  • Neurocops: the Politics of Prohibition and the Future of Enforcing Social Policy from Inside the Body
    NEUROCOPS: THE POLITICS OF PROHIBITION AND THE FUTURE OF ENFORCING SOCIAL POLICY FROM INSIDE THE BODY RICHARD GLEN BOIRE1 I. INTRODUCTION .................................................................... 216 II. FROM DEMAND REDUCTION TO DESIRE REDUCTION.......................................................................... 216 III. PHARMACOTHERAPY DRUGS ............................................... 218 A. Target: Opiates............................................................ 218 B. Target: Cocaine........................................................... 221 C. Target: Marijuana....................................................... 222 D. Targeting Legal Drugs ................................................ 223 1. Target: Nicotine.................................................... 223 2. Target: Alcohol..................................................... 225 E. Pharmacotherapy Drugs: Good, Bad, Both, or Beyond?......................................................... 225 F. From Drug War to Drug Epidemic ............................. 230 IV. NEUROCOPS: LEGAL ISSUES RAISED BY COMPULSORY PHARMACOTHERAPY..................................... 234 A. Privacy and Liberty Interests Implicated by Involuntary Pharamacotherapy.............................. 234 B. Informed Consent......................................................... 236 C. At Risk Targets for Coercive Pharmacotherapy ........................................................ 238 1. Pharmacotherapy and Public Education.............................................................
    [Show full text]
  • Comment Letter
    July 23, 2008 Subject: Follow-up on July 22 Meeting Dr. Sirri et al.: I thank you for meeting with Ken Salomon, John Welborn and me yesterday afternoon to discuss Reg SHO, naked short selling and the SEC's recent emergency order. As a follow-up, I want to emphasize the following points: 1. OSTK continues to believe that it is critical that the SEC extend the pre-borrow requirement of the emergency order to the entire market, not just the 19 select companies. OSTK requests that the SEC promptly undertake swift rulemaking so that this protection applies fairly across the market. 2. OSTK continues to support the prompt and full elimination of the option market maker exception, an exception that swallows up the good intentions of Reg SHO. During yesterday's meeting, we discussed the relationship between the markets for equities and their corresponding derivatives (including listed options). You stated that options market makers enjoy an exception from the Reg SHO requirement that they locate and/or deliver shares when hedging against options positions. I am not sure that I would read Reg SHO to say that. However, under your theory, if an options market maker sells a put with a 6- month expiration, then that same market maker has the legal right to naked short and fail to deliver an equivalent amount of the underlying equity (leaving the option market maker "delta neutral”) for six months. This exception is unnecessary and open to abuse/manipulation, particularly with the married puts that often occur in Reg SHO threshold securities.
    [Show full text]
  • Modulation of Immune Responses Using Adjuvants to Facilitate Therapeutic Vaccination
    Received: 6 March 2020 | Revised: 30 April 2020 | Accepted: 20 May 2020 DOI: 10.1111/imr.12889 INVITED REVIEW Modulation of immune responses using adjuvants to facilitate therapeutic vaccination Virgil Schijns1 | Alberto Fernández-Tejada2,3 | Žarko Barjaktarović4 | Ilias Bouzalas5 | Jens Brimnes6 | Sergey Chernysh7,† | Sveinbjorn Gizurarson8 | Ihsan Gursel9 | Žiga Jakopin10 | Maria Lawrenz11 | Cristina Nativi12 | Stephane Paul13 | Gabriel Kristian Pedersen14 | Camillo Rosano15 | Ane Ruiz-de-Angulo2 | Bram Slütter16 | Aneesh Thakur17 | Dennis Christensen14 | Ed C. Lavelle18 1Wageningen University, Cell Biology & Immunology and, ERC-The Netherlands, Schaijk, Landerd campus, The Netherlands 2Chemical Immunology Lab, Center for Cooperative Research in Biosciences, CIC bioGUNE, Biscay, Spain 3Ikerbasque, Basque Foundation for Science, Bilbao, Spain 4Agency for Medicines and Medical Devices of Montenegro, Podgorica, Montenegro 5Hellenic Agricultural Organization-DEMETER, Veterinary Research Institute, Thessaloniki, Greece 6Alk Abello, Copenhagen, Denmark 7Laboratory of Insect Biopharmacology and Immunology, Department of Entomology, Saint-Petersburg State University, Saint-Petersburg, Russia 8Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland 9Bilkent University, Ankara, Turkey 10Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia 11Vaccine Formulation Institute (CH), Geneva, Switzerland 12Department of Chemistry, University of Florence, Florence, Italy 13St Etienne University, St Etienne, France 14Statens
    [Show full text]
  • View Annual Report
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission file number 001-35023 iBio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2797813 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 9 Innovation Way, Suite 100, Newark, DE 19711 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (302) 355-0650 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered Common Stock, $0.001 par value NYSE MKT Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Gsk Vaccines in 2010
    GSK VACCINES IN 2010 Thomas Breuer, MD, MSc Senior Vice President Head of Global Vaccines Development GSK Biologicals Vaccines business characteristics Few global players and high barriers to entry – Complex manufacturing – Large scale investment Long product life cycles – Complex intellectual property High probability of R&D success – 70% post-POC New technology/novel products Better pricing for newer vaccines – HPV vaccines (Cervarix, Gardasil) – Pneumococcal vaccines (Synflorix, Prevnar-13) Operating margin comparable to pharmaceutical products Heightened awareness New markets 2 Research & development timelines Identify Produce Pre-Clinical Proof of Registration/ Phase I Phase II Phase III File Antigens Antigens Testing Concept Post Marketing Research (inc. Immunology) Pre-Clinical Development (inc. Formulation Science) Clinical Development (inc. Post Marketing Surveillance) Transfer Process to Manufacturing Build Facility x x Up to $10-20M Up to $50-100M $500M - $1B x x x 1-10 yrs 2-3 yrs 2-4 yrs > 1 yr GSK vaccines business 2009 sales £3.7 billion (+30%) +19% CAGR excl. H1N1 Vaccines represent 13% since 2005 of total GSK sales Sale s (£m) 4000 3500 Recent approvals: 3000 US: Cervarix 2500 EU: Synflorix 2000 Pandemic: Pandemrix; Arepanrix 1500 1000 500 0 2005 2006 2007 2008 2009 Increased Emerging Market presence Growth rate is CER 5 GSK vaccines: fastest growing part of GSK in 2009 2009 Sales Share Growth (CER) Respiratory £ 6,977m 25% +5% Consumer £ 4,654m 16% +7% Anti-virals £ 4,150m 15% +12% Vaccines £ 3,706m 13% +30% CV & Urogenital
    [Show full text]
  • Antigen Discovery in Trypanosoma Vivax
    Antigen discovery in Trypanosoma vivax Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy by Alessandra Isabella Romero Ramirez February 2020 Author’s declaration The expression of recombinant proteins was performed by Dr. Nicole Muller-Sienerth at the Cell Surface Signalling Laboratory from the Wellcome Trust Sanger Institute (Cambridge, UK). The mice immunization and challenge was carried out by Dr. Delphine Autheman from the Cell Surface Signalling Laboratory at the animal facility from the Wellcome Trust Sanger Institute. The immunization and challenge of goats as well as sample collection was performed by MSc. Kayo José Garcia de Almeida Castilho Neto at the Faculty of Agricultural and Veterinary Sciences from the Sao Paulo State University (UNESP) in Jaboticabal, Sao Paulo, Brazil. Except from the advice acknowledged, I declare that this thesis is a presentation of my own original work. Alessandra Isabella Romero Ramirez 20th February 2020 I ACKNOWLEDGEMENTS First of all, I would like to express my sincere gratitude to my PhD thesis supervisor, Dr. Andrew Jackson for his guidance throughout the project, patience and belief in me. I highly appreciate his motivation, immense knowledge and critical advice during these years. I am truly thankful for the guidance and opportunities given. I gratefully acknowledge the funding body that made my PhD work possible. I was funded by FONDECYT-CONCYTEC, the National Council of Science, Technology and Innovation from Peru (grant contract number 001-2016-FONDECYT). I would specially like to acknowledge members from the Cell Surface Signalling laboratory at the Wellcome Sanger Institute, to the group leader Gavin Wright, postdoctoral Delphine Autheman and the senior technician Nicole Muller-Sienerth for their enormous contribution on this doctoral project.
    [Show full text]
  • Significant Items
    DEPARTMENT of HEALTH and HUMAN SERVICES FISCAL YEAR 2008 NATIONAL INSTITUTES OF HEALTH - Volume III Overview -- Significant Items Justification of Estimates for Appropriations Committees SIGNIFICANT ITEMS (SIs) FY 2007 House Appropriations Committee Report 109-515 and FY 2007 Senate Appropriations Committee Report 109-287 Table of Contents National Institutes of Health – Institutes and Centers National Cancer Institute (NCI) ...................................................................................... 1 National Heart, Lung, and Blood Institute (NHLBI)..................................................... 23 National Institute of Dental and Craniofacial Research (NIDCR) ................................. 41 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).............. 45 National Institute of Neurological Disorders and Stroke (NINDS)................................ 73 National Institute of Allergy and Infectious Diseases (NIAID) .................................. 101 National Institute of General Medical Sciences (NIGMS)............................................ 123 National Institute of Child Health and Human Development (NICHD) ....................... 127 National Eye Institute (NEI) ......................................................................................... 153 National Institute of Environmental Health Sciences (NIEHS) ..................................... 155 National Institute of Aging (NIA) ................................................................................. 163 National
    [Show full text]
  • European Biotechnology | Summer Edition | Vol
    I S S N 2 3 6 4 - 2 351 | A 6 0 711 | Interview Hospira’s Paul Greenland talks European about the launch Life Sciences and of the first mAb Industry Magazine biosimilar and the new challenges in Biotechnology Summer Edition 2015 | Volume 14 | 20 € development. Financing European biotech companies have added crowdinvesting to the fi nancing toolbox Nagoya Protocol Poor implementation of benefi t sharing could block Tracking biotech innovation in Europe Antibiotics New EU fi nancing instrument to close funding gap in high- stealthy risk antibiotic development EuroBioFairsCompass The unique guide to the top life killers sciences events in the second half of 2015 FREE EXCERPT Liquid Biopsy 4 CONTENTS European Biotechnology | Summer Edition | Vol. 14 | 2015 FREE EXCERPT COVER STORY INSIGHT EUROPE REGIONAL NEWS 6 European Commission opens 42 Northern Europe: fl oodgates for GM imports Sweden, Denmark, Finland, and Norway 10 First genome-edited crops to be stamped non-GMO by Member 44 Western Europe: States; Heard in Brussels France, Belgium, The Netherlands and the UK 12 European Commission and Euro- pean Investment Bank set to 46 Central Europe: launch new fi nancing instrument Austria, Germany and Switzerland for high-risk antibiotics develop- ment; Horizon2020 call focuses 48 Southern Europe: on personalised medicine; UK lags Italy, Spain, Portugal, Cyprus & Malta behind EU in fi ght against cancer; MEPs demand no dilution of EU life 50 Eastern Europe: sciences rules through TTIP Poland and the Czech Republic ECONOMY PICK & MIX 22 Interview: Paul
    [Show full text]